The Developability Classification System (DCS) is a modification of the well-established Biopharmaceutics Classification System (BCS) that focuses on the underlying reasons of poorly soluble compounds: Dissolution rate limitations (DCS IIa) and solubility limitations (DCS IIb). By using the DCS, we will focus on how Meglumine, an amino sugar, can support in solving challenges with poorly soluble compounds as well as API stability and how it can be used in advanced manufacturing technologies such as hot melt extrusion (HME).
In this webinar, you will learn:
- How the developability classification system emerged from the well-established biopharmaceutics classification system.
- How the DCS can distinguish between solubility and dissolution rate limited compounds.
- How Meglumine can help with improving solubility.
- Which other formulation challenges Meglumine can solve.
Speaker
Erik Peiter
{hcompany}
Strategic Marketing Manager – Excipients Solid Application
Erik is a strategic marketing manager for our portfolio of functional excipients. He has more than 10 years of experience in the pharmaceutical excipients industry with a focus on the formulation of solid dosage forms. He holds a B.Sc. degree in biology from Heidelberg University as well as a B.A. begree in business administration from Cooperative State University Mannheim.
Pharma and biopharma manufacturing
- Downstream Processing
Duration:1h
Language:English
Session 1:presented March 7, 2023
To continue reading please sign in or create an account.
Don't Have An Account?